File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline

TitleChemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline
Authors
Issue Date2021
PublisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://www.jco.org/
Citation
Journal of Clinical Oncology, 2021, v. 39 n. 7, p. 840-859 How to Cite?
AbstractPURPOSE: The aim of this joint guideline is to provide evidence-based recommendations to practicing physicians and other healthcare providers on definitive-intent chemoradiotherapy for patients with stage II-IVA nasopharyngeal carcinoma (NPC). METHODS: The Chinese Society of Clinical Oncology (CSCO) and ASCO convened an expert panel of radiation oncology, medical oncology, surgery, and advocacy representatives. The literature search included systematic reviews, meta-analyses, and randomized controlled trials published from 1990 through 2020. Outcomes of interest included survival, distant and locoregional disease control, and quality of life. Expert panel members used this evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS: The literature search identified 108 relevant studies to inform the evidence base for this guideline. Five overarching clinical questions were addressed, which included subquestions on radiotherapy (RT), chemotherapy sequence, and concurrent, induction, and adjuvant chemotherapy options. RECOMMENDATIONS: Evidence-based recommendations were developed to address aspects of care related to chemotherapy in combination with RT for the definitive-intent treatment of stage II to IVA NPC. Additional information is available at www.asco.org/head-neck-cancer-guidelines.
Persistent Identifierhttp://hdl.handle.net/10722/295516
ISSN
2020 Impact Factor: 44.544
2020 SCImago Journal Rankings: 10.482
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChen, YP-
dc.contributor.authorIsmaila, N-
dc.contributor.authorChua, MLK-
dc.contributor.authorColevas, AD-
dc.contributor.authorHaddad, R-
dc.contributor.authorHuang, SH-
dc.contributor.authorWee, JTS-
dc.contributor.authorWhitley, AC-
dc.contributor.authorYi, JL-
dc.contributor.authorYom, SS-
dc.contributor.authorChan, ATC-
dc.contributor.authorHu, CS-
dc.contributor.authorLang, JY-
dc.contributor.authorLe, QT-
dc.contributor.authorLee, AWM-
dc.contributor.authorLee, N-
dc.contributor.authorLin, JC-
dc.contributor.authorMa, B-
dc.contributor.authorMorgan, TJ-
dc.contributor.authorShah, J-
dc.contributor.authorSun, Y-
dc.contributor.authorMa, J-
dc.date.accessioned2021-01-25T11:15:59Z-
dc.date.available2021-01-25T11:15:59Z-
dc.date.issued2021-
dc.identifier.citationJournal of Clinical Oncology, 2021, v. 39 n. 7, p. 840-859-
dc.identifier.issn0732-183X-
dc.identifier.urihttp://hdl.handle.net/10722/295516-
dc.description.abstractPURPOSE: The aim of this joint guideline is to provide evidence-based recommendations to practicing physicians and other healthcare providers on definitive-intent chemoradiotherapy for patients with stage II-IVA nasopharyngeal carcinoma (NPC). METHODS: The Chinese Society of Clinical Oncology (CSCO) and ASCO convened an expert panel of radiation oncology, medical oncology, surgery, and advocacy representatives. The literature search included systematic reviews, meta-analyses, and randomized controlled trials published from 1990 through 2020. Outcomes of interest included survival, distant and locoregional disease control, and quality of life. Expert panel members used this evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS: The literature search identified 108 relevant studies to inform the evidence base for this guideline. Five overarching clinical questions were addressed, which included subquestions on radiotherapy (RT), chemotherapy sequence, and concurrent, induction, and adjuvant chemotherapy options. RECOMMENDATIONS: Evidence-based recommendations were developed to address aspects of care related to chemotherapy in combination with RT for the definitive-intent treatment of stage II to IVA NPC. Additional information is available at www.asco.org/head-neck-cancer-guidelines.-
dc.languageeng-
dc.publisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://www.jco.org/-
dc.relation.ispartofJournal of Clinical Oncology-
dc.titleChemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline-
dc.typeArticle-
dc.identifier.emailLee, AWM: awmlee@hkucc.hku.hk-
dc.identifier.authorityLee, AWM=rp02056-
dc.identifier.doi10.1200/JCO.20.03237-
dc.identifier.pmid33405943-
dc.identifier.scopuseid_2-s2.0-85102322450-
dc.identifier.hkuros320983-
dc.identifier.volume39-
dc.identifier.issue7-
dc.identifier.spage840-
dc.identifier.epage859-
dc.identifier.isiWOS:000635371200016-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats